RATIONALE: Most genomic studies of lung function have used phenotypic data derived from a single time-point (e.g., presence/absence of disease) without considering the dynamic progression of a chronic disease. OBJECTIVES: To characterize lung function change over time in subjects with asthma and identify genetic contributors to a longitudinal phenotype. METHODS: We present a method that models longitudinal FEV1 data, collected from 1,041 children with asthma who participated in the Childhood Asthma Management Program. This longitudinal progression model was built using population-based nonlinear mixed-effects modeling with an exponential structure and the determinants of age and height. MEASUREMENTS AND MAIN RESULTS: We found ethnicity was a key covariate for FEV1 level. Budesonide-treated children with asthma had a slight but significant effect on FEV1 when compared with those treated with placebo or nedocromil (P < 0.001). A genome-wide association study identified seven single-nucleotide polymorphisms nominally associated with longitudinal lung function phenotypes in 581 white Childhood Asthma Management Program subjects (P < 10(-4) in the placebo ["discovery"] and P < 0.05 in the nedocromil treatment ["replication"] group). Using ChIP-seq and RNA-seq data, we found that some of the associated variants were in strong enhancer regions in human lung fibroblasts and may affect gene expression in human lung tissue. Genetic mapping restricted to genome-wide enhancer single-nucleotide polymorphisms in lung fibroblasts revealed a highly significant variant (rs6763931; P = 4 × 10(-6); false discovery rate < 0.05). CONCLUSIONS: This study offers a strategy to explore the genetic determinants of longitudinal phenotypes, provide a comprehensive picture of disease pathophysiology, and suggest potential treatment targets.
RATIONALE: Most genomic studies of lung function have used phenotypic data derived from a single time-point (e.g., presence/absence of disease) without considering the dynamic progression of a chronic disease. OBJECTIVES: To characterize lung function change over time in subjects with asthma and identify genetic contributors to a longitudinal phenotype. METHODS: We present a method that models longitudinal FEV1 data, collected from 1,041 children with asthma who participated in the Childhood Asthma Management Program. This longitudinal progression model was built using population-based nonlinear mixed-effects modeling with an exponential structure and the determinants of age and height. MEASUREMENTS AND MAIN RESULTS: We found ethnicity was a key covariate for FEV1 level. Budesonide-treated children with asthma had a slight but significant effect on FEV1 when compared with those treated with placebo or nedocromil (P < 0.001). A genome-wide association study identified seven single-nucleotide polymorphisms nominally associated with longitudinal lung function phenotypes in 581 white Childhood Asthma Management Program subjects (P < 10(-4) in the placebo ["discovery"] and P < 0.05 in the nedocromil treatment ["replication"] group). Using ChIP-seq and RNA-seq data, we found that some of the associated variants were in strong enhancer regions in human lung fibroblasts and may affect gene expression in human lung tissue. Genetic mapping restricted to genome-wide enhancer single-nucleotide polymorphisms in lung fibroblasts revealed a highly significant variant (rs6763931; P = 4 × 10(-6); false discovery rate < 0.05). CONCLUSIONS: This study offers a strategy to explore the genetic determinants of longitudinal phenotypes, provide a comprehensive picture of disease pathophysiology, and suggest potential treatment targets.
Entities:
Keywords:
FEV1; NONMEM; asthma; longitudinal model
Authors: Stanley Szefler; Scott Weiss; James Tonascia; N Franklin Adkinson; Bruce Bender; Reuben Cherniack; Michele Donithan; H William Kelly; Joseph Reisman; Gail G Shapiro; Alice L Sternberg; Robert Strunk; Virginia Taggart; Mark Van Natta; Robert Wise; Margaret Wu; Robert Zeiger Journal: N Engl J Med Date: 2000-10-12 Impact factor: 91.245
Authors: Scott Smemo; Juan J Tena; Kyoung-Han Kim; Eric R Gamazon; Noboru J Sakabe; Carlos Gómez-Marín; Ivy Aneas; Flavia L Credidio; Débora R Sobreira; Nora F Wasserman; Ju Hee Lee; Vijitha Puviindran; Davis Tam; Michael Shen; Joe Eun Son; Niki Alizadeh Vakili; Hoon-Ki Sung; Silvia Naranjo; Rafael D Acemel; Miguel Manzanares; Andras Nagy; Nancy J Cox; Chi-Chung Hui; Jose Luis Gomez-Skarmeta; Marcelo A Nóbrega Journal: Nature Date: 2014-03-12 Impact factor: 49.962
Authors: Anna Gref; Simon K Merid; Olena Gruzieva; Stéphane Ballereau; Allan Becker; Tom Bellander; Anna Bergström; Yohan Bossé; Matteo Bottai; Moira Chan-Yeung; Elaine Fuertes; Despo Ierodiakonou; Ruiwei Jiang; Stéphane Joly; Meaghan Jones; Michael S Kobor; Michal Korek; Anita L Kozyrskyj; Ashish Kumar; Nathanaël Lemonnier; Elaina MacIntyre; Camille Ménard; David Nickle; Ma'en Obeidat; Johann Pellet; Marie Standl; Annika Sääf; Cilla Söderhäll; Carla M T Tiesler; Maarten van den Berge; Judith M Vonk; Hita Vora; Cheng-Jian Xu; Josep M Antó; Charles Auffray; Michael Brauer; Jean Bousquet; Bert Brunekreef; W James Gauderman; Joachim Heinrich; Juha Kere; Gerard H Koppelman; Dirkje Postma; Christopher Carlsten; Göran Pershagen; Erik Melén Journal: Am J Respir Crit Care Med Date: 2017-05-15 Impact factor: 21.405
Authors: Erick Forno; Joanne Sordillo; John Brehm; Wei Chen; Takis Benos; Qi Yan; Lydiana Avila; Manuel Soto-Quirós; Michelle M Cloutier; Angel Colón-Semidey; Maria Alvarez; Edna Acosta-Pérez; Scott T Weiss; Augusto A Litonjua; Glorisa Canino; Juan C Celedón Journal: J Allergy Clin Immunol Date: 2017-02-04 Impact factor: 10.793